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Hepatitis B virus, hepatitis C virus and human immunodeﬁciency virus share a similar
transmission  pathway and are often diagnosed in the same patient. These patients tend to
have a faster progression of hepatic ﬁbrosis. This cross-sectional study describes the demo-
graphic  features and clinical proﬁle of human immunodeﬁciency virus/hepatitis co-infected
patients  in Paraná, Southern Brazil. A total of 93 human immunodeﬁciency virus-infected
patients  attending a tertiary care academic hospital in Southern Brazil were included. Clini-
cal,  demographic and epidemiological data were evaluated. Hepatitis B virus and/or hepatitis
C  virus positive serology was found in 6.6% of patients. The anti-hepatitis C virus serum
test  was positive in 85% (79/93) of patients, and the infection was conﬁrmed in 72% of the
cases.  Eighteen patients (19%) were human immunodeﬁciency virus/hepatitis B virus posi-
tive  (detectable HBsAg). Among co-infected patients, there was a high frequency of drug use,
and investigations for the detection of co-infection were conducted late. A low number of
patients were eligible for treatment and, although the response to antiretroviral therapy was
good, there was a very poor response to hepatitis therapy. Our preliminary ﬁndings indicate
the  need for protocols aimed at systematic investigation of hepatitis B virus and hepatitis Cvirus in human immunodeﬁciency virus-infected patients, thus allowing for early detection
and  treatment of co-infected patients.
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Fig. 1 – HIV/HCV co-infected patients: HCV genotypesb r a z j i n f e c t d i s .
Worldwide, 350 and 180 million people are estimated to
ave  chronic hepatitis C virus (HCV) and hepatitis B virus
HBV),  respectively. Overall, 20–30% of HCV patients and
–10%  of chronic HBV individuals are co-infected with human
mmunodeﬁciency virus (HIV).1 Highly active antiretroviral
herapy (HAART) has improved the clinical outcomes of
IV-infected patients and decreased the rates of morbid-
ty  and mortality by reducing the incidence of opportunistic
nfections. According to Brazilian government data, the free
vailability  of antiretroviral drugs to all HIV-infected patients
ecreased  the mortality rate due to AIDS by 49% and reduced
ospital  admissions by 7.5 fold, conﬁrming the efﬁcacy of the
nstituted  therapy.2 However, as a result of the higher life
xpectancy, chronic diseases caused by HBV and HCV infec-
ions,  together with antiretroviral drugs hepatotoxicity, have
ecome  important causes of morbidity and mortality in HIV
nfected  patients.3
In Brazil, the most common risk factors for HIV/HBV co-
nfection  are sexual intercourse, especially in men  who have
ex  with men  (MSM), and intravenous drug use (IDU).4–6 The
orldwide prevalence of HBV/HIV co-infection is heteroge-
eous  and in Brazilian health service clinics, it ranges between
.3%  and 24.3%.7,8 HIV-infected patients are at a 5–6 times
igher risk of becoming chronic carriers of HBV, show higher
ates  of reactivation, and progress more  frequently to cirrhosis
nd  hepatocellular carcinoma.9,10
In most cases, the concomitant infection with HIV and HCV
s  associated with percutaneous exposure, especially IDU.11
he Brazilian health services have reported HIV/HCV preva-
ence  rates of 9.2–54.7%,7,8,12–15 HIV/HCV co-infection leads
o  higher HCV viral load, more  intense hepatic inﬂamma-
ion  and necrosis, and is associated with earlier progression
o  hepatic insufﬁciency and cirrhosis as compared to mono-
nfected  patients.16,17
The prevalence of HBV and/or HCV co-infection in HIV
atients varies signiﬁcantly across geographic regions. The
resent  study investigated the prevalence, epidemiological
eatures, and clinical evolution of HBV and/or HCV and HIV
o-infection  cases in patients treated at an HIV referral center
n  Paraná State, Southern Brazil.
This is a cross-sectional study carried out in a tertiary
are academic hospital; patients were  prospectively included
rom  March 2011 through March 2013. The Institutional Review
oard  of HC/UFPR approved the study (IRB# 2304.198/2010/08).
One hundred eight-one co-infected patients were  identi-
ed  by analysis of database, of these 93 patients met  the study
nclusion  criteria: age >18 years; positive serology for HIV (anti-
IV),  HBV (HBV-speciﬁc antigens and antibodies), and/or HCV
anti-HCV)  registered in the respective medical record; and
oluntary  participation by written informed consent. Patients
ith  incomplete medical information, children, no follow-up
isit  to the clinic in the last three years, and those who did not
gree  to participate in the study were excluded.
An epidemiological survey was  carried out using a
uestionnaire designed to obtain information regarding edu-
ational  level, sexual practices, past or present history of
rug  abuse, alcohol consumption, blood transfusion prior to
IV diagnosis, tattooing, and body piercing. The researchers
onducted personal interviews in a private and conﬁden-
ial  environment. The information obtained from patients’frequency.
medical records included demographic data (age, sex, race),
anti-HCV  result, qualitative/quantitative polymerase chain
reaction  (PCR) for HCV, HCV genotyping, HBV serological data
(HBsAg,  anti-HBc, anti-HBs), ultrasound and liver biopsy ﬁnd-
ings  (ﬁbrosis, steatosis, siderosis, cirrhosis), previous HBV or
HCV treatment (treatment duration, drugs used, response to
therapy), date of HIV infection, HIV viral load (last result), CD4+
T cell count (nadir and last result), and HAART use. Patients
treated  for chronic hepatitis C were considered to be cured if
sustained virologic response was  achieved six months after
completion  of therapy.
Data  were compiled using JMP software, version 5.2.1 SAS
Institute  Inc., Cary, NC, 1989–2004 and analyzed by Graph-
Pad  Prism version 5.03 for Windows, GraphPad Software, La
Jolla,  CA. The 95% conﬁdence intervals (CI) were  adopted, all
p-values  were two-tailed, and a value of <0.05 was  considered
statistically signiﬁcant.
HIV/hepatitis co-infection occurred in 6.6% of the cases.
HCV  serology was  positive in 85% (79/93) of individuals: 57
(72%)  cases had qualitative PCR-conﬁrmed infection, 12 (15%)
cases  were  PCR negative, and 10 (13%) patients were  not
investigated by PCR. Eighteen patients (19%) were  positive for
HIV/HBV co-infection.
HCV  and HBV infection occurred predominantly in male
Caucasians with a low to moderate educational level. Further-
more,  the majority of patients were heterosexual, with less
than  two sexual partners per year (61.5%), and intravenous
drug users (50%) (Table 1).
In general, the studied patients had a long-standing HIV
infection  or AIDS, with a median duration of 11 years (IQR,
8–14),  and 62 patients (66%) had undetectable viral load and
showed  an improvement of cell immunity with a median of
143  cells/mm3 and 406 cells/mm3 for nadir and current CD4+
T cell count, respectively.
The  HCV genotype was  analyzed in 49 patients (49/57, 86%),
and  genotype 1 was  the most prevalent (33/49, 67%) (Fig. 1).
Hepatic  disease was  investigated by abdominal ultrasound in
68% (39/57,) of cases and by liver biopsy in 65% (37/57). Fibrosis
was  the most frequent ﬁnding in biopsies.
Twenty-eight patients received therapy with pegylated
interferon and ribavirin, and out of these patients, only 33%
developed  sustained virologic response (SVR). However, anal-
ysis  of the SVR rate among patients with distinct genotypes
revealed that genotype 1 patients had the worst response to
treatment, with only 23.5% SVR.
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Table 1 – Demographic, epidemiological, and laboratory characteristics of HIV/Hepatitis co-infected patients.
Characteristics HIV/HCV
n = 57(%)
HIV/HBV
n  = 18
p  value
Gender
Male 35 (61.5) 16 (89) 0.041
Female 22 (38.5) 2 (11)
Age (y, median) 47 41 0.049
IQR (42–53) (37.7–51.5)
Race 0.884
White 32 (56) 12 (66.5)
Afro-descendent 15 (26.5) 4 (22.5)
Asian 1 (1.5) –
NI  9 (16) 2 (11)
Years of study 0.393
1–3 years 5 (9) 1 (5)
4–7 years 18 (31.5) 4 (22)
8–11 years 17 (30) 3 (17)
≥12 years 6 (10.5) 3 (17)
NI 11 (19) 7 (39)
Drug use 0.488
Yes 36 (56) 8 (44.5)
IV 24 (61.5) 4 (50)
Other 12 (38.5) 4 (50)
No 17 (30) 6 (33.5)
NI 8 (14) 4 (22)
Sexual behavior 0.0016
MSM 2 (3.5) 4 (22)
Heterosexual 42 (73.5) 5 (28)
Bisexual 2 (3.5) 3 (17)
NI 11 (19.5) 6 (33)
Number of partners 0.054
<2 years 34 (59.5) 5 (28)
2–5 years 2 (3.5) 3 (16.5)
>5 years 8 (14) 3 (16.5)
NI 13 (23) 7 (39)
Hepatitis diagnosis time (y, median) 7  0.030
IQR (5–9.5) 6 (4.5–7)
Hepatitis treatment NA
Yes 28 (49) 16 (89)
SVR 9 (32) –
Null response 16 (57.5) 4 (25)
Relapse 1 (3.5) –
Withdrew 2 (7) 2 (12.5)
Inadequate – 3 (18.5)
NI – 7 (44)
No 29 (51) 2 (11)
HIV diagnosis time (y, median) 11 12 0.676
IQR (8–14) (4.7–15)
HIV viral load 0.150
Detectable 21 (37) 3 (17)
(Median, IQR) 668 (171–37,480) 18,446 (1620–38,436)
Undetectable 36 (53) 15 (83)
CD4+ LT value (median, IQR)
Nadir  139 (75–265.5) 164 (42.7–274.7) 0.995
Current 288 (270.5–531) 465.5 (318.3–749.3) 0.155
HAART use 0.141
Yes 56 (98) 16 (89)
No 1 (2) 2 (11)
NI, not informed; IQR, interquartile range; y, years.
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A total of 88 patients (95%) were investigated for HBV
nfection. The frequency of HBsAg positive patients was  20%
18/88).  Only 7/88 (8%) of these individuals had single anti-HBs
ntibodies, and 12/88 (13%) had anti-HBs and total anti-HBc
ntibodies. Forty-three patients (49%) did not have any anti-
odies  against HBV.
Twelve  patients received a regimen, which included dual
herapy  of lamivudine and tenofovir for HBV, but three
atients received only one drug – lamivudine – and another
atient was  not given HBV-speciﬁc therapy.
This is the ﬁrst study to investigate HIV/hepatitis co-
nfection in Paraná. The co-infection frequency, its clinical
mpact,  the lack of adequate anti-HCV serum test screening,
nd  inadequate therapeutic response emphasize the need
or  training of health professionals in the management of
o-infection  cases and the necessity for rapid therapeutic
trategies against this serious public health problem.
Despite the development of novel and more  effective
herapies, hepatic disease in co-infected patients remains
omplicated and costly to treat. Therefore, prevention of
hronic  infection should be a priority.18 However, despite the
uidelines  recommendation for systematic and routine lab-
ratory  investigation of co-infection, it is still not performed
n  referral centers where the prevalence of high-risk patients,
uch  as IDUs, is low.
In  the majority of cases, the diagnosis of viral hepatitis was
ade  after the diagnosis of HIV. This suggests a late diagnosis
f  hepatitis or that the infection occurred after the diagnosis
f  HIV. A continuous educational approach about STDs should
e  enforced in health care services to prevent co-infection.
It  should be emphasized that the update of the Brazilian
uidelines and, consequently, the recommendation to intro-
uce  HAART treatment earlier to co-infected patients was
vailable  only after 2010; until then, detection of hepatic dis-
ase  in patients with a CD4+ T cell count <350 cells/mm3 was
ot  followed by speciﬁc HIV therapy. Consequently, risk factor-
ased  screening failed to identify most individuals infected
ith  HCV, and in patients who had positive anti-HCV sero-
ogy,  the conﬁrmation of infection by PCR was  not routinely
erformed.
The  high frequency of HIV/HCV co-infection, the small
umber of patients eligible for treatment, and reduced clin-
cal  response observed in our study were similar to previous
eports. Usually, approximately 15–45% of HCV co-infected
atients have viral clearance. In this study, SVR was  observed
n  33% of the cases, and 20–30% of patients with persistent
iremia may  develop liver ﬁbrosis, and potentially cirrhosis,
iver  failure, and hepatocellular carcinoma.19 These ﬁndings
ighlight the necessity for timely diagnosis and treatment as
ell as serious harm-reduction programs  seeking to control
nd  eliminate HCV infection and transmission among these
atients.20
Many  patients were  only screened once for HCV infection
uring their follow-up, and ongoing screening was  not usu-
lly  performed because HIV typically has shorter latency until
anifestation  and is brought to clinical attention sooner than
CV.  However, these patients remain at risk for liver infection,
nd  yearly testing for HCV antibodies and liver function abnor-
alities  in HIV-infected MSM  and IDUs are both necessary and
ost  effective.4;1 8(6):664–668  667
As previously reported, low RVS rates were  observed among
the  patients eligible for therapy. The treatment approach is
complex  and requires intensive monitoring and support to
achieve  viral eradication. Nevertheless, HCV therapy should
be  provided if the potential beneﬁts of therapy outweigh
the  potential risk of treatment-related toxicity. Overall, 20%
of  the investigated patients were HIV/HBV co-infected, and
this  frequency was  lower than that of HCV/HIV co-infection.
Nonetheless, this frequency is 20-fold higher the prevalence
described in the general population of this region. In this
study,  we  observed that some co-infected patients were  in
monotherapy for their hepatitis. It should be noted that, in
an  attempt to achieve better control of the HIV infection, the
physician  might have chosen not to maintain the treatment
for  the hepatitis co-infection. However, when the antiretrovi-
ral  drugs need to be changed for any reason (i.e., side effects,
HIV  virological failure, or drug interactions) and even when the
patient  has complete HBV suppression, drugs active against
HBV  should be included in the new regimen.1 A total of 9%
of  the patients had only anti-HBc antibodies, and such sero-
logical  results should be further investigated to determine if
they are false-positive and to detect a “serologically silent” or
occult HBV infection found in individuals with negative HBsAg
but  detectable serum HBV-DNA.
In conclusion, information about co-infection in devel-
oping  countries, such as Brazil, is unavailable, and sero-
logical  surveillance studies to determine the prevalence of
HIV/Hepatitis co-infection in the HIV referral centers should
be  encouraged. All HIV-positive patients should be periodically
screened for HCV and HBV co-infection, seeking to assess the
rate  and the clinical consequence of the co-infection. The sig-
niﬁcant  risk of adverse effects and the high pharmacologic
complexity of managing co-infected patients highlight the
need  for ongoing training of health professionals and more
effective  HBV and HCV infection-prevention strategies.
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